Novartis Vaccines, Via Fiorentina 1, 53100 Siena, Italy.
J Mol Med (Berl). 2010 Feb;88(2):143-7. doi: 10.1007/s00109-009-0574-9.
The hundreds of bacterial genome sequences available together with advances in bioinformatics and the development of new experimental proteomic tools are revolutionizing the vaccinology field. The merge of stringent in silico criteria and different experimental approaches is allowing a more targeted strategy to obtain a restricted and prioritized list of potential antigens for testing in immunogenicity assays, reducing the time and the cost of novel protein vaccine formulations.
数百个细菌基因组序列的出现,加上生物信息学的进步和新的实验蛋白质组学工具的发展,正在彻底改变疫苗学领域。严格的计算机筛选标准和不同实验方法的结合,使得人们能够采取更有针对性的策略,获得潜在抗原的有限且优先列表,用于免疫原性检测,从而缩短新型蛋白质疫苗配方的开发时间和降低成本。